121 related articles for article (PubMed ID: 30611870)
41. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.
Uchida H; Maruyama T; Nagashima T; Asada H; Yoshimura Y
Endocrinology; 2005 Dec; 146(12):5365-73. PubMed ID: 16123169
[TBL] [Abstract][Full Text] [Related]
42. DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling.
Savickiene J; Treigyte G; Jazdauskaite A; Borutinskaite VV; Navakauskiene R
Cell Biol Int; 2012 Nov; 36(11):1067-78. PubMed ID: 22845560
[TBL] [Abstract][Full Text] [Related]
43. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
[TBL] [Abstract][Full Text] [Related]
44. Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes.
Hofmann WK; Kalina U; Wagner S; Seipelt G; Ries C; Hoelzer D; Ottmann OG
Exp Hematol; 1999 Mar; 27(3):395-400. PubMed ID: 10089900
[TBL] [Abstract][Full Text] [Related]
45. The HDAC6 Inhibitor Tubacin Induces Release of CD133
Chao OS; Chang TC; Di Bella MA; Alessandro R; Anzanello F; Rappa G; Goodman OB; Lorico A
J Cell Biochem; 2017 Dec; 118(12):4414-4424. PubMed ID: 28452069
[TBL] [Abstract][Full Text] [Related]
46. The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming.
Borutinskaitė V; Navakauskienė R
Int J Mol Sci; 2015 Aug; 16(8):18252-69. PubMed ID: 26287160
[TBL] [Abstract][Full Text] [Related]
47. Histone deacetylase inhibitors promote osteoblast maturation.
Schroeder TM; Westendorf JJ
J Bone Miner Res; 2005 Dec; 20(12):2254-63. PubMed ID: 16294278
[TBL] [Abstract][Full Text] [Related]
48. Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling.
Valiuliene G; Stirblyte I; Cicenaite D; Kaupinis A; Valius M; Navakauskiene R
J Cell Mol Med; 2015 Jul; 19(7):1742-55. PubMed ID: 25864732
[TBL] [Abstract][Full Text] [Related]
49. Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?
Shen S; Kozikowski AP
ChemMedChem; 2016 Jan; 11(1):15-21. PubMed ID: 26603496
[TBL] [Abstract][Full Text] [Related]
50. Estrogen promotes megakaryocyte polyploidization via estrogen receptor beta-mediated transcription of GATA1.
Du C; Xu Y; Yang K; Chen S; Wang X; Wang S; Wang C; Shen M; Chen F; Chen M; Zeng D; Li F; Wang T; Wang F; Zhao J; Ai G; Cheng T; Su Y; Wang J
Leukemia; 2017 Apr; 31(4):945-956. PubMed ID: 27748371
[TBL] [Abstract][Full Text] [Related]
51. HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells.
Mazzio EA; Soliman KF
Cancer Genomics Proteomics; 2017 Jan; 14(1):17-33. PubMed ID: 28031235
[TBL] [Abstract][Full Text] [Related]
52. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
53. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation.
Bouchain G; Delorme D
Curr Med Chem; 2003 Nov; 10(22):2359-72. PubMed ID: 14529479
[TBL] [Abstract][Full Text] [Related]
54. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
55. Valproic acid regulates erythro-megakaryocytic differentiation through the modulation of transcription factors and microRNA regulatory micro-networks.
Trécul A; Morceau F; Gaigneaux A; Schnekenburger M; Dicato M; Diederich M
Biochem Pharmacol; 2014 Nov; 92(2):299-311. PubMed ID: 25241289
[TBL] [Abstract][Full Text] [Related]
56. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Jazirehi AR
Anticancer Drugs; 2010 Oct; 21(9):805-13. PubMed ID: 20679890
[TBL] [Abstract][Full Text] [Related]
57. Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism.
Hrgovic I; Doll M; Pinter A; Kaufmann R; Kippenberger S; Meissner M
Exp Dermatol; 2017 Feb; 26(2):194-201. PubMed ID: 27487811
[TBL] [Abstract][Full Text] [Related]
58. HIV-1 negatively affects the survival/maturation of cord blood CD34(+) hematopoietic progenitor cells differentiated towards megakaryocytic lineage by HIV-1 gp120/CD4 membrane interaction.
Gibellini D; Vitone F; Buzzi M; Schiavone P; De Crignis E; Cicola R; Conte R; Ponti C; Re MC
J Cell Physiol; 2007 Feb; 210(2):315-24. PubMed ID: 17111363
[TBL] [Abstract][Full Text] [Related]
59. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
[TBL] [Abstract][Full Text] [Related]
60. The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker.
Yang F; Zhao N; Hu Y; Jiang CS; Zhang H
Chem Biodivers; 2020 Jan; 17(1):e1900427. PubMed ID: 31793143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
